Irbesartan Crescent Pharma (Irbesartan)

Irbesartan works by selectively antagonising the angiotensin II type 1 (AT1) receptor. By blocking this receptor, it prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation, resulting in vasodilation, reduced sodium and water retention, and lower systemic blood pressure.

The appropriate dose of Irbesartan Crescent Pharma is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and renal function. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the dose on their own.

Irbesartan is generally contraindicated during the second and third trimesters of pregnancy because it may harm the developing fetus. Safety during breastfeeding has not been established, so clinicians usually advise against use while nursing unless the benefits outweigh potential risks.

To order Irbesartan Crescent Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Irbesartan belongs to the ARB class, which blocks the AT1 receptor downstream of the ACE step. Compared with ACE inhibitors, ARBs like Irbesartan are less likely to cause cough or angio‑edema, but both classes provide similar blood‑pressure‑lowering effects. Choice between them depends on patient tolerance, comorbidities, and physician preference.

Irbesartan Crescent Pharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in a refrigerator or freezer, and ensure the container is tightly closed when not in use.

Irbesartan Crescent Pharma is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or split the tablet unless specifically instructed.

Serious risks include hyperkalemia (elevated potassium levels), acute kidney injury, and angio‑edema, which can be life‑threatening. Patients should be alert for symptoms such as swelling of the face or throat, rapid weight gain, decreased urine output, or muscle weakness, and seek medical attention promptly if they occur.

Irbesartan Crescent Pharma should be avoided in patients with known hypersensitivity to irbesartan or any component of the formulation, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for individuals with severe renal dysfunction or uncontrolled hyperkalemia.